Replacing efavirenz (EFV) with raltegravir (RAL) in antiretroviral therapy (ART) may decrease hepatotoxicity in patients who are coinfected with HIV and hepatitis C virus (HCV).
Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.
A long-acting therapy may be noninferior to the current daily oral antiretroviral therapy (ART) in maintaining viral suppression in the treatment of HIV-1 infection.
Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis, according to research results presented at the virtual Conference on Retroviruses and Opportunistic Infections, held from March 8 to 11, 2020. Two groups of researchers examined the role of hepatic steatosis across these patient populations.…
The transmission of direct-acting antiviral (DAA) resistance-associated substitutions (RAS) may inhibit hepatitis C virus (HCV) cure rates and elimination efforts.
A child with intrauterine-acquired HIV who received antiretroviral therapy (ART) at 33 hours after birth through age 13 months showed persistent undetectable HIV viremia more than 3 years after discontinuing ART.